Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment
Background: MiR-106a and miR-20a (miR-17 family members) are frequently dysregulated in carcinogenesis, but their prognostic significance in acute myeloid leukemia (AML) remains unclear.Methods: We analyzed miR-106a and miR-20a expression in bone marrow from 115 AML patients and 45 healthy controls...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2025.2533577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061673880092672 |
|---|---|
| author | Yue Liu Jiayu Liu Yuehua Feng Xiaoguang Xu Yingjie Miao Huijuan Chen Yu Zhou Yijun Pan Yan Liu Weiying Gu Yang Cao |
| author_facet | Yue Liu Jiayu Liu Yuehua Feng Xiaoguang Xu Yingjie Miao Huijuan Chen Yu Zhou Yijun Pan Yan Liu Weiying Gu Yang Cao |
| author_sort | Yue Liu |
| collection | DOAJ |
| description | Background: MiR-106a and miR-20a (miR-17 family members) are frequently dysregulated in carcinogenesis, but their prognostic significance in acute myeloid leukemia (AML) remains unclear.Methods: We analyzed miR-106a and miR-20a expression in bone marrow from 115 AML patients and 45 healthy controls using qRT-PCR. Additionally, we utilized TCGA data (n=188) to assess the association of these miRNAs with clinical factors and outcomes. Prognostic analysis evaluated the impact of miR-106a and miR-20a on overall survival (OS) and event-free survival (EFS). Differentially expressed genes (DEGs) were identified using Limma. GO and KEGG pathway analyses were performed by DAVID. GSEA and PPI were constructed using ClusterProfiler and STRING database.Results: MiR-106a and miR-20a elevated in AML versus healthy controls. In chemotherapy group, miR-106ahigh or miR-20ahigh predicted poor OS and EFS, with dual-high expression conferring the worst outcome. In allo-HSCT group, miR-106ahigh or miR-20ahigh predicted poor OS but similar EFS, with dual-high cases showing the worst OS. In the miR-106ahigh or miR-20ahigh group, allo-HSCT prolonged OS (but not EFS) versus chemotherapy. In the miR-106alow or miR-20alow group, there were no obvious differences in OS or EFS between the chemotherapy and allo-HSCT regimens. Multivariable analyses confirmed miR-106a/miR-20a signature as an independent prognostic marker. Moreover, we identified 706 signature-associated DEGs. Bioinformatic analysis illuminated the involvement of miR-106a and miR-20a in regulating diverse biological processes and signaling pathways.Conclusions: MiR-106a and miR-20a are promising AML prognostic biomarkers for adverse outcome. The combined signature improves risk stratification and guides therapy selection (e.g., allo-HSCT for high-risk cases). |
| format | Article |
| id | doaj-art-8eea4b311b8840bd98b48b8a142f23f1 |
| institution | DOAJ |
| issn | 1607-8454 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-8eea4b311b8840bd98b48b8a142f23f12025-08-20T02:50:08ZengTaylor & Francis GroupHematology1607-84542025-12-0130110.1080/16078454.2025.2533577Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatmentYue Liu0Jiayu Liu1Yuehua Feng2Xiaoguang Xu3Yingjie Miao4Huijuan Chen5Yu Zhou6Yijun Pan7Yan Liu8Weiying Gu9Yang Cao10Department of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaComprehensive Laboratory, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaBackground: MiR-106a and miR-20a (miR-17 family members) are frequently dysregulated in carcinogenesis, but their prognostic significance in acute myeloid leukemia (AML) remains unclear.Methods: We analyzed miR-106a and miR-20a expression in bone marrow from 115 AML patients and 45 healthy controls using qRT-PCR. Additionally, we utilized TCGA data (n=188) to assess the association of these miRNAs with clinical factors and outcomes. Prognostic analysis evaluated the impact of miR-106a and miR-20a on overall survival (OS) and event-free survival (EFS). Differentially expressed genes (DEGs) were identified using Limma. GO and KEGG pathway analyses were performed by DAVID. GSEA and PPI were constructed using ClusterProfiler and STRING database.Results: MiR-106a and miR-20a elevated in AML versus healthy controls. In chemotherapy group, miR-106ahigh or miR-20ahigh predicted poor OS and EFS, with dual-high expression conferring the worst outcome. In allo-HSCT group, miR-106ahigh or miR-20ahigh predicted poor OS but similar EFS, with dual-high cases showing the worst OS. In the miR-106ahigh or miR-20ahigh group, allo-HSCT prolonged OS (but not EFS) versus chemotherapy. In the miR-106alow or miR-20alow group, there were no obvious differences in OS or EFS between the chemotherapy and allo-HSCT regimens. Multivariable analyses confirmed miR-106a/miR-20a signature as an independent prognostic marker. Moreover, we identified 706 signature-associated DEGs. Bioinformatic analysis illuminated the involvement of miR-106a and miR-20a in regulating diverse biological processes and signaling pathways.Conclusions: MiR-106a and miR-20a are promising AML prognostic biomarkers for adverse outcome. The combined signature improves risk stratification and guides therapy selection (e.g., allo-HSCT for high-risk cases).https://www.tandfonline.com/doi/10.1080/16078454.2025.2533577AMLmiR-106amiR-20achemotherapyallo-HSCTprognosis |
| spellingShingle | Yue Liu Jiayu Liu Yuehua Feng Xiaoguang Xu Yingjie Miao Huijuan Chen Yu Zhou Yijun Pan Yan Liu Weiying Gu Yang Cao Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment Hematology AML miR-106a miR-20a chemotherapy allo-HSCT prognosis |
| title | Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment |
| title_full | Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment |
| title_fullStr | Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment |
| title_full_unstemmed | Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment |
| title_short | Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment |
| title_sort | prognostic value of mir 106a and mir 20a in aml patients with chemotherapy or allo hsct treatment |
| topic | AML miR-106a miR-20a chemotherapy allo-HSCT prognosis |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2025.2533577 |
| work_keys_str_mv | AT yueliu prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT jiayuliu prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yuehuafeng prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT xiaoguangxu prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yingjiemiao prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT huijuanchen prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yuzhou prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yijunpan prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yanliu prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT weiyinggu prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment AT yangcao prognosticvalueofmir106aandmir20ainamlpatientswithchemotherapyorallohscttreatment |